List view / Grid view
13 May 2019 | By Unjulie Bhanot
There are many business challenges to developing a biologics drug, one of which is effective data management. In this article, Unjulie Bhanot focuses on efficient data management policies and systems, and how they could improve biologics product development processes.
3 May 2019 | By Alice Laures - GSK, Lisa Wysocki - GSK, Paul J Newby - GSK
Modernisation of microbiological test methods involves far more than just the science. As new systems and technologies become available it becomes increasingly important that potential users can identify not only the technical requirements, but also the business case. Here, Paul Newby, Alice Laures and Lisa Wysocki from GlaxoSmithKline discuss criteria…
26 February 2019 | By European Pharmaceutical Review
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
20 February 2019 | By European Pharmaceutical Review
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
25 September 2018 | By Mike Stones
The new hub is designed to speed the response to deadly pandemics by improving the development and manufacturing of vaccines – particularly in low- and middle-income countries...
1 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new study has found a blood test for cancer DNA could predict if a woman is responding to the new breast cancer drug palbociclib, months earlier than current tests...
4 January 2018 | By Beatriz Faro - Pfizer
For Pfizer, putting patients first guides its actions, informs its strategic decisions and unifies colleagues in every region and function across the company. Beatriz Faro, Regional President, Internal Medicine, International Developed Markets at Pfizer, explains how the company’s philosophy is taking the business forward...
2 January 2018 | By Christof Hohne
Christof Hohne, partner at patent law firm EIP, discusses second medical use claims and compulsory licences...
21 December 2017 | By European Pharmaceutical Review
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
4 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Mylotarg for the treatment of adults with newly diagnosed acute myeloid leukaemia whose tumours express the CD33 antigen...
25 July 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
13 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
16 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
15 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
The FDA has granted fast track designation for Pfizer and Eli Lilly’s tanezumab for the treatment of chronic pain in patients with osteoarthritis...
6 June 2017 | By Niamh Marriott, Junior Editor
Regulatory submissions to the EMA and FDA for a single-tablet, two-drug regimen of dolutegravir & rilpivirine for the maintenance treatment of HIV...
Follow: